These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
472 related articles for article (PubMed ID: 33678158)
1. The association of sex-biased ATRX mutation in female gastric cancer patients with enhanced immunotherapy-related anticancer immunity. Ge Y; Wei F; Du G; Fei G; Li W; Li X; Chu J; Wei P BMC Cancer; 2021 Mar; 21(1):240. PubMed ID: 33678158 [TBL] [Abstract][Full Text] [Related]
2. The mutational pattern of homologous recombination (HR)-associated genes and its relevance to the immunotherapeutic response in gastric cancer. Fan Y; Ying H; Wu X; Chen H; Hu Y; Zhang H; Wu L; Yang Y; Mao B; Zheng L Cancer Biol Med; 2020 Nov; 17(4):1002-1013. PubMed ID: 33299649 [TBL] [Abstract][Full Text] [Related]
3. Cytolytic activity score as a biomarker for antitumor immunity and clinical outcome in patients with gastric cancer. Hu Q; Nonaka K; Wakiyama H; Miyashita Y; Fujimoto Y; Jogo T; Hokonohara K; Nakanishi R; Hisamatsu Y; Ando K; Kimura Y; Masuda T; Oki E; Mimori K; Oda Y; Mori M Cancer Med; 2021 May; 10(9):3129-3138. PubMed ID: 33769705 [TBL] [Abstract][Full Text] [Related]
4. Alterations in TP53 Are a Potential Biomarker of Bladder Cancer Patients Who Benefit From Immune Checkpoint Inhibition. Lyu Q; Lin A; Cao M; Xu A; Luo P; Zhang J Cancer Control; 2020; 27(1):1073274820976665. PubMed ID: 33356494 [TBL] [Abstract][Full Text] [Related]
5. Identification of Deleterious Zhang K; Hong X; Song Z; Xu Y; Li C; Wang G; Zhang Y; Zhao X; Zhao Z; Zhao J; Huang M; Huang D; Qi C; Gao C; Cai S; Gu F; Hu Y; Xu C; Wang W; Lou Z; Zhang Y; Liu L Clin Cancer Res; 2020 Jul; 26(14):3649-3661. PubMed ID: 32241817 [TBL] [Abstract][Full Text] [Related]
6. EPHA7 mutation as a predictive biomarker for immune checkpoint inhibitors in multiple cancers. Zhang Z; Wu HX; Lin WH; Wang ZX; Yang LP; Zeng ZL; Luo HY BMC Med; 2021 Feb; 19(1):26. PubMed ID: 33526018 [TBL] [Abstract][Full Text] [Related]
7. Age, sex, and specific gene mutations affect the effects of immune checkpoint inhibitors in colorectal cancer. Lin A; Zhang H; Hu X; Chen X; Wu G; Luo P; Zhang J Pharmacol Res; 2020 Sep; 159():105028. PubMed ID: 32569820 [TBL] [Abstract][Full Text] [Related]
8. Huang T; Liang Y; Zhang H; Chen X; Wei H; Sun W; Wang Y Genes (Basel); 2021 Oct; 12(11):. PubMed ID: 34828321 [TBL] [Abstract][Full Text] [Related]
9. Association of MUC16 Mutation With Tumor Mutation Load and Outcomes in Patients With Gastric Cancer. Li X; Pasche B; Zhang W; Chen K JAMA Oncol; 2018 Dec; 4(12):1691-1698. PubMed ID: 30098163 [TBL] [Abstract][Full Text] [Related]
10. Prevalence of PRKDC mutations and association with response to immune checkpoint inhibitors in solid tumors. Chen Y; Li Y; Guan Y; Huang Y; Lin J; Chen L; Li J; Chen G; Pan LK; Xia X; Xu N; Chang L; Guo Z; Pan J; Yi X; Chen C Mol Oncol; 2020 Sep; 14(9):2096-2110. PubMed ID: 32502294 [TBL] [Abstract][Full Text] [Related]
11. Combination of AKT1 and CDH1 mutations predicts primary resistance to immunotherapy in dMMR/MSI-H gastrointestinal cancer. Wang Z; Zhang Q; Qi C; Bai Y; Zhao F; Chen H; Li Z; Wang X; Chen M; Gong J; Peng Z; Zhang X; Cai J; Chen S; Zhao X; Shen L; Li J J Immunother Cancer; 2022 Jun; 10(6):. PubMed ID: 35705314 [TBL] [Abstract][Full Text] [Related]
12. Pan-cancer analysis of CDKN2A alterations identifies a subset of gastric cancer with a cold tumor immune microenvironment. Deng C; Li ZX; Xie CJ; Zhang QL; Hu BS; Wang MD; Mei J; Yang C; Zhong Z; Wang KW Hum Genomics; 2024 May; 18(1):55. PubMed ID: 38822443 [TBL] [Abstract][Full Text] [Related]
13. Chemokine receptor 4 expression is correlated with the occurrence and prognosis of gastric cancer. Li Y; Wang HC; Wang JS; Sun B; Li LP FEBS Open Bio; 2020 Jun; 10(6):1149-1161. PubMed ID: 32306562 [TBL] [Abstract][Full Text] [Related]
14. Alteration in TET1 as potential biomarker for immune checkpoint blockade in multiple cancers. Wu HX; Chen YX; Wang ZX; Zhao Q; He MM; Wang YN; Wang F; Xu RH J Immunother Cancer; 2019 Oct; 7(1):264. PubMed ID: 31623662 [TBL] [Abstract][Full Text] [Related]
15. A Signature-Based Classification of Gastric Cancer That Stratifies Tumor Immunity and Predicts Responses to PD-1 Inhibitors. Li S; Gao J; Xu Q; Zhang X; Huang M; Dai X; Huang K; Liu L Front Immunol; 2021; 12():693314. PubMed ID: 34177954 [TBL] [Abstract][Full Text] [Related]
16. Intra-tumoral heterogeneity and immune responses predicts prognosis of gastric cancer. Feng W; Wang Y; Chen S; Zhu X Aging (Albany NY); 2020 Nov; 12(23):24333-24344. PubMed ID: 33259333 [TBL] [Abstract][Full Text] [Related]
17. RB1 and TP53 co-mutations correlate strongly with genomic biomarkers of response to immunity checkpoint inhibitors in urothelial bladder cancer. Manzano RG; Catalan-Latorre A; Brugarolas A BMC Cancer; 2021 Apr; 21(1):432. PubMed ID: 33879103 [TBL] [Abstract][Full Text] [Related]
18. The Predictive Value of PAK7 Mutation for Immune Checkpoint Inhibitors Therapy in Non-Small Cell Cancer. Zeng H; Tong F; Bin Y; Peng L; Gao X; Xia X; Yi X; Dong X Front Immunol; 2022; 13():834142. PubMed ID: 35242138 [TBL] [Abstract][Full Text] [Related]
19. Development and interpretation of a pathomics-based model for the prediction of microsatellite instability in Colorectal Cancer. Cao R; Yang F; Ma SC; Liu L; Zhao Y; Li Y; Wu DH; Wang T; Lu WJ; Cai WJ; Zhu HB; Guo XJ; Lu YW; Kuang JJ; Huan WJ; Tang WM; Huang K; Huang J; Yao J; Dong ZY Theranostics; 2020; 10(24):11080-11091. PubMed ID: 33042271 [TBL] [Abstract][Full Text] [Related]
20. Association of MUC16 Mutation With Response to Immune Checkpoint Inhibitors in Solid Tumors. Zhang L; Han X; Shi Y JAMA Netw Open; 2020 Aug; 3(8):e2013201. PubMed ID: 32845327 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]